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Background
Genetic contribution of TNFὰ–308 promoter and
T676G TNF-RII polymorphism on response to TNF-
blocking agents in JIA is not yet well established.
Methods
Genomic DNA was extracted and TNFὰ–308 promoter
and T676G TNF-RII polymorphism was evaluated using
the PCR-RFLP method in 60 JIA patients treated with
etanercept. Time cut of point for outcome data analysis
was 4 years.
Results
Average duration of etanercept therapy was 34.61±12.11
months. Disease subtype distribution was 6.78% sys-
temic, 54.24% poly RF- and extended-oligo, 18.64% poly
RF+, 16.95% ERA and 3.38 PsA. The distribution of
TNFὰ308 and T676G genotypes was not significantly
different among JIA subtypes. TNFὰ308 genotypes dis-
tribution was 6.78% AA, 30.51% GG and 62.71% GA
while T676G genotypes were 59.3% TT, 8.3% GG and
26.4% TG. T676G genotype polymorphism did not sig-
nificantly influenced outcome. ACR Pedi 30,50,70 and
100 improvement was significantly faster and sustained
in TNFὰ308 GG-genotype patients compared to GA
genotype (results shown in table:*significant compared
to 1 year; a-significant compared to GG). Treatment
induced remission in 35.14%, had to be reintroduced
due to disease worsening in 16.22%, disease was in
remission under medication in 21.62% or still active in
24.32% GA patients and in 38.9%, 16.7%, 27.8% and
11.1% in GG patients, respectively. Patients with sys-
t e m i co rR F +d i s e a s ec o u r s ew e r em o s t l yt r e a t m e n t
resistant in both genotypes. (Table 1)
Conclusion
JIA patients with GG TNFὰ308 genotype can achieve
better outcome and etanercept treatment can be
stopped earlier compared to GA genotype patients who
need two years of treatment to achieve same results.
TNFὰ308 genotype could be useful clinical predictive
biomarker for treatment response in all disease subtypes
except systemic and RF positive JIA.
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Table 1
ACR 30 50 70 100
% G G G A G GG A G G G A G GG A
1 year 5.6 18.9
a 22.2 35.14
a 22.2 32.43
a 50.9 13.51
a
2 years 14.71
a 5.6* 17.65*
a 44.4* 44.12* 50.0 23.52*
a
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